STAT3 and Its Pathways' Dysregulation-Underestimated Role in Urological Tumors

Cells. 2022 Sep 27;11(19):3024. doi: 10.3390/cells11193024.

Abstract

Nowadays, molecular research is essential for the better understanding of tumor cells' pathophysiology. The increasing number of neoplasms is taken under 'the molecular magnifying glass'; therefore, it is possible to discover the complex relationships between cytophysiology and tumor cells. Signal transducer and activator of transcription 3 (STAT3) belongs to the family of latent cytoplasmic transcription factors called STATs, which comprises seven members: STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, and STAT6. Those proteins play important role in cytokine-activated gene expression by transducing signals from the cell membrane to the nucleus. Abnormal prolonged activation results in tumorigenesis, metastasis, cell proliferation, invasion, migration, and angiogenesis. Inhibition of this transcription factor inhibits the previously mentioned effects in cancer cells, whereas normal cells are not affected. Hence, STAT3 might be a viable target for cancer therapy.

Keywords: STAT3; bladder cancer; penile cancer; prostate cancer; renal cell carcinoma; testicular cancer; upper tract urothelial carcinoma.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cytokines / metabolism
  • Humans
  • STAT3 Transcription Factor* / metabolism
  • Signal Transduction
  • Urologic Neoplasms*

Substances

  • Cytokines
  • STAT3 Transcription Factor
  • STAT3 protein, human

Grants and funding

The paper was funded partially by the Department of Molecular and Cellular Biology, grant no. SUB.D260.22.016, and partially by the University Center of Excellence in Urology, the Department of Minimally Invasive and Robotic Urology, grant no. SUBZ.C090.22.057.